iifl-logo-icon 1

Biocon Ltd Share Price

375.95
(2.96%)
Dec 2, 2024|01:14:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open375
  • Day's High380
  • 52 Wk High395.8
  • Prev. Close365.15
  • Day's Low368.05
  • 52 Wk Low 236.15
  • Turnover (lac)27,512.85
  • P/E0
  • Face Value5
  • Book Value90.92
  • EPS0.35
  • Mkt. Cap (Cr.)45,136.56
  • Div. Yield0.14
View All Historical Data
Loading...
  • Roll Over%0
  • Roll Cost0
View More Futures

Biocon Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

375

Prev. Close

365.15

Turnover(Lac.)

27,512.85

Day's High

380

Day's Low

368.05

52 Week's High

395.8

52 Week's Low

236.15

Book Value

90.92

Face Value

5

Mkt Cap (₹ Cr.)

45,136.56

P/E

0

EPS

0.35

Divi. Yield

0.14

Biocon Ltd Corporate Action

3 Oct 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

16 May 2024

12:00 AM

Dividend

Dividend Amount: 0.5

Record Date: 05 Jul, 2024

arrow

16 May 2024

12:00 AM

AGM

Announcement Date: 16 May, 2024

arrow

Biocon Ltd NEWS AND UPDATE

Biocon Secures FDA Approval for Innovative Autoimmune Drug YESINTEK
1 Dec 2024|11:20 PM

YESINTEK targets specific proteins that trigger inflammation, which presents new therapeutic options in the chronic management of autoimmune diseases.

Read More
Biocon Biologics collaborates with Diabetes Africa
28 Nov 2024|03:12 PM

Ethiopia, with a prevalence of 2-3%, is one of the top four nations in Sub-Saharan Africa for adult diabetics.

Read More
Biocon Shares Surge on USFDA VAI Designation
11 Nov 2024|12:27 PM

The combined cGMP inspection and pre-licensing inspection (PLI), which took place between July 15 and July 26, 2024, is the subject of this update.

Read More
Top stocks for today - 11th November 2024
11 Nov 2024|12:08 PM

Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.

Read More
Biocon Shares Plunge 6% on Profit Miss
31 Oct 2024|01:08 PM

The company's operating revenue climbed 3.7% to Rs 3,590.4 crore from Rs 3,462 crore in Q2 of FY24.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Biocon Ltd SHAREHOLDING SNAPSHOT

02 Dec, 2024|01:32 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 20.27%

Foreign: 20.27%

Indian: 40.36%

Non-Promoter- 20.36%

Institutions: 20.36%

Non-Institutions: 18.75%

Custodian: 0.24%

Share Price

Biocon Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

600.3

600.3

600.3

600

Preference Capital

0

0

0

0

Reserves

10,312

10,315.7

7,492.6

7,307.1

Net Worth

10,912.3

10,916

8,092.9

7,907.1

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

1,738.2

2,028.4

1,988.4

2,419.2

yoy growth (%)

-14.3

2.01

-17.8

-6.51

Raw materials

-808.2

-798.3

-827.7

-1,049.4

As % of sales

46.49

39.35

41.62

43.37

Employee costs

-367.7

-390.2

-344.8

-408.6

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

139.7

358.8

388.5

305.8

Depreciation

-108.2

-103.5

-98

-136.1

Tax paid

-53.6

-78.3

-111.9

-67.3

Working capital

268.3

64.09

379.5

-311.6

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-14.3

2.01

-17.8

-6.51

Op profit growth

-80.44

9.26

-10.11

-46.23

EBIT growth

-60.99

-7.82

27.02

-43.18

Net profit growth

-69.3

-36.38

84.86

-54.07

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

14,195.8

11,174.2

8,184

7,143.1

6,300.5

Excise Duty

0

0

0

0

0

Net Sales

14,195.8

11,174.2

8,184

7,143.1

6,300.5

Other Operating Income

559.9

0

0

0

0

Other Income

865.5

375.9

212.7

267.1

228.9

Biocon Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,780.9

155.064,27,477.51863.290.765,123.6798.33

Divis Laboratories Ltd

DIVISLAB

6,172.7

89.181,63,821.995180.492,302513.62

Cipla Ltd

CIPLA

1,533.9

29.271,23,920.061,178.160.853,969.86360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,324.2

68.821,12,592.364600.842,376222.38

Mankind Pharma Ltd

MANKIND

2,561.2

51.211,02,659.66634.4302,529.74269.23

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Biocon Ltd

Management

Register Office

Registrar Office

Chairperson

Kiran Mazumdar Shaw

Non Executive Director

Ravi Mazumdar

Lead Independent Director

M Damodaran

Independent Director

Bobby Parikh

Company Sec. & Compli. Officer

Mayank Verma

Managing Director & CEO

SIDDHARTH MITTAL

Non Executive Director

Eric Vivek Mazumdar

Independent Director

Naina Lal Kidwai

Independent Director

Atul Dhawan

Independent Director

Rekha Mehrotra Menon

Independent Director

NICHOLAS ROBERT HAGGAR

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing facilit
Read More

Company FAQs

What is the Biocon Ltd share price today?

The Biocon Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹375.95 today.

What is the Market Cap of Biocon Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biocon Ltd is ₹45136.56 Cr. as of 02 Dec ‘24

What is the PE and PB ratio of Biocon Ltd?

The PE and PB ratios of Biocon Ltd is 0 and 4.02 as of 02 Dec ‘24

What is the 52 Week High and Low of Biocon Ltd?

The 52-week high/low is the highest and lowest price at which a Biocon Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Biocon Ltd is ₹236.15 and ₹395.8 as of 02 Dec ‘24

What is the CAGR of Biocon Ltd?

Biocon Ltd's CAGR for 5 Years at 5.33%, 3 Years at 0.07%, 1 Year at 54.23%, 6 Month at 12.84%, 3 Month at 2.73% and 1 Month at 11.67%.

What is the shareholding pattern of Biocon Ltd?

The shareholding pattern of Biocon Ltd is as follows:
Promoters - 60.64 %
Institutions - 20.37 %
Public - 18.75 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp